Clinical Trial Update: Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating combined metabolic activator supplementation in Alzheimer's disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Combined Metabolic Activator

Snippet

Sponsor: ScandiBio Therapeutics AB | Conditions: Alzheimer Disease | Phase 3 | Status: RECRUITING